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D936104 Prophylaxis of Atrial Fibrillation FollowingElectrical Cardioversion. A Prospective
Randomized Study Comparing Low-Doee and
Very LOW-DOSSAmlodarone to Propafenone:
Preliminary Remtlte
F.Aequati,F. Forgione, S. Caico, C. Saveri, E. Miglierina, S. Roeei,
S. Repetto, G. Sinaghi. Division of CardiObgM General Hospital of Varese,
Italy
In patients (pts) with chronic atrial fibrillation (AF), restoration of sinus rhythm
(SR) osn be easily achieved by pharmacological or electrical cardioversion
(EC) but reiapse ratea are high, even with the use of antiarrhythmic drugs
(AA). In June 1995 we planned a single-center, prospective, open-label,
randomized study comparing the aafety and effioecy of amiodarone (A) vs
propafenone (P) in maintaining SR in 150 pts with chronic AF successfully
submitted to EC. Pts were randomized to reoeive Iow-doae A (200 mg/day,
group A), very iow-doeeA(100 mglday, group S)or P (675 mgt.i.d., group C).
Ptssesigned to A receiveda Ioadingdose of 1500 mg inthe24hourefollowing
EC. Pts with poet-surgery AF (PSAF) or AF during an acute myocardial
infarction (AMIAF) and ptewith mntraindication to AA [sinus node diefunetion
(SND) and A-V”eonduction defects (AVCD)] were not included in the study.
Ptawith thyroid disease (TO)andshoti-term planned eerdiacsurgery (STCS)
were aieo excluded. Age> 75 yeare, LVEF <407. and left atrial enlargement
were not criteria of exciusion. All pts were then axamined and a 12-lead
ECG obtained at, 1, 3, 6, 12 months of follow-up or when they experienced
symptome suggestive for AF recurrence. From June 1995 to June 1996, 66
pte (54%), out from 159 p~auccessfully submitted to EC, were enrolled.
Reasons for exclusion (73 pts) were: PSAF in 20 (27%), AMIAF in 12 (16%),
TD in 11 (15%), STCS in 9 (12%), SND or AVCD in 12 (16%), refus@
informed consent in 9 pts (12%). Thirty one pte were randomized to group
A, 25 to group B and 30 to group C. Age, sex, underlying heart disease, AF
duration, body weight, left atrial diameter and LVEF were not significantly
different between groups. At a mean follow-up of 7.3 + 3.6 months (range
1-14 months) 25 pte (61%) of group A were still in SR compared to 19 pts
(76%) of group B (p = na) and 17 pts (57%) of group C (p <0.05 vs group
A and p = ns va group S). No serious aide effect was reported, but 2 pte
reduced P for intestinal discomfort and 1 pt died for non-cardiac causes.
Cono/usions: Our preliminary date indicate that Iow-doaeA is a aafe and
effective treatment, superior to P,for maintaining SR after EC for chronic AF.
A similar trend of efficacy can be showed for very low-dose of A.
-1 Pain ThreehO,dfor,nterna, CardiovereionWith
Low or no Sedation
R. Ammer, E. Alt, G. Lehmann, C. Schmitt, J. Pasquantonio, A. Plewan,
K. PMter, A. Sch6mig. L Med. Klinik, Klinikum rechts derlsac Technische
Universit2itMtirrchen, Germany
Seckground: Reoent studies have shown that internal cerdioversion (IC) of
atriai fibriiiatlon (AF) is effective. In this prospective atudy, we have tried to
evaluate the influence of different waveforms on the perception of pain during
IC in patients (pts) with chronic AF.
Methods: IC was performed with low or no sedation in 19 pts. R-wave
triggered, biphasic waveforms of 6 ins/6 ms or 3 ma/3 ms pulse length
(randomly seleoted) and approximately 65% tilt were used starting with a 60
volt (V) test ehcck, then increased in 40 V steps up to a maximum voltage of
520V. Shookewere appiiedvia2 custom-made eleotrode catheters (Eleeath,
Rahway, NJ). In 11 pts (3 female, age 61 * 11 years, LA-diameter 58 + 5
mm, duration of AF 4 + 4 months), &’8 waveforms were used, and in 8 pts
(2 female, age 62 + 5 years, LA-diameter 59 + 5 mm, AF duration 5 +
3 months, none significant), EU3waveforms were used. After cerdiovemion,
each patient was asked to quantify his pain on a scale from 1 to 10 (1 = no
pain, 10= intolerable).
Resu/ts:All ptawere auccesafullycardioverted. Ptsfromthe6/6 waveform
group were convatied to sinus rhythm with lower voltage and lower pain.
Wavsform[ma] 6/6 3/3 p-value
Pain*ore (1-10) 1.3 * 1.1 4.2 & 2.0 p <0.05
Midazolam~mg] 2.3 & 1.8 5.6 & 2.3 p <0.05
CardioveraionEnergy[J] 6.6* 2.8 6.3+ 1.5 n.s,
VoltagepJl 251/114 306/170 p <0.05
Cone/usions:The waveform used in internal derdiovereion seems to have
a major impaot on the patients’ perception of pain. The resulta imply that
energy determines the auooess of a shook, but voltage determine the pain
perceived bythe patient. The uaeof waveforms that deliver greater energy at
iower peak voltages offers the possibility of IC with less sedation and greater
patient tolerance.
EmElImpaired Quality of Life in Patients With AtrielFibrillation ia not Related to AF Frequency or
Duration
M. Paquette, E. Mancuso,”J. Kuruvilla, D. Newman, P. Dorian. The
University of Toronto, Toronto, Canada
The impact of atrial fibrillation (AF) on quality of life (QOL) Is unclear. The
symptom burden and degree of life disruption is highly variable, and may
not be related to objective indices such as frequency or duration of AF
epiecdas. Thirty-five AF patients completed the Medical Outcomes Study
(SF-36), University of Toronto Arrhythmia Sesle (U of T), and the Barsky
Somatization Scale. The frequency, duration, and peroeived aever’ty of AF
episodes were aiso recorded.
Resu/te: 80% of patients were male and median age waa 64 years.
AF was paroxysmal in 45%; 29% and 26% had permanent and persistent
AF, respectively. Median epiaode frequency was 2.5/week with an average
severity rating of 4.9 + 1.3 on a 10 point viaual analog scale.
SF-36 Scele AF CAD Normals
PhysicalFunction 65+ 29* 70& 26 64 k 23
Role-Physical 39• 41*t 51 *40 81 &34
%cial Function 74 + 19*t 85& 21 83& 23
Vitality 47 * 25*t 58& 19 61 &21
General Health 55& 23” 59• 19 72& 20
*p< O.Ot,AFvs. Normals;tp <0.01, AFvs. CAD (r&ent Ml)
Tendeneyto somatize was correlated with lower general health scores on
the SF-36 (by multipie regression, R2= 0.29, p < 0.01). However, frequency
and duration.of episodes were not correlated with any QOL domains (R2 =
0.04-0.10).
Conclusions: QOL is as much or more impaired in patients with AF than
CAD patients; perception of QOL ia unrelated to objective measurea of
disease burden usually empioyed to assess treatment efficacy in AF.
e] ReappraiaalofOptimal lnitialEnergyfor Externel
Cardioversion of Atrial Flutter
S.L. Pinski, E.B. Sgarbosaa, F.J.Jaeger, D. Bash, M. Tobin, R.G. Trohman.
Cleveland Clinic, Cleveland, Ohio, USA
Direct-current cardioversion is oommonly used to restore sinus rhythm in
patients with atrial flutter. Currentiy, initial energies of 25 to 50 J are recom-
mended. However, the optimal energy settings have not been evaluated in
a large aaries of contemporary patients. We compared the effioacy of 50 J
vs. 100J in 296 consecutive patients who underwent their first attempted ex-
ternal esrdioversion for typical atrial flutter. Initial energy wea chosen based
on attending physician preference. One hundred thirty four patients (45%)
received 50 J, and 162 (55%) 100 J. Patients in both groups did not dif-
fer in age, gender, weight, duration of the arrhythmia, postoperative statue,
presence and type of structural heart diseaee, or use of antiarrhythmic druge
(inciuding amiodarone). Patients in the 100 J group had higher incidence
of firet shock oonveraion (83’%vs. 67Yo;p = 0.002), fewer number of total
shocks (1.2 + 0.5 vs. 1.4 + 0.7; p = 0.005), and a trend towards ahorter
procedural room time (39 minutee vs. 54 minutea; p = 0.06). There were no
differences in overall restoration of ainus rhythm (96% vs. 97%), total energy
delivered (152 + 146 J vs. 129* 145 J), or methohexital dose (0.68 + 0.3
vs. 0.69 + 0.3 mg/kg)..No acute complications occurred. Conclusions: an
initial energy of 100 J appeara to be a more efficient choice for restoration of
sinus rhythm in patiente with atrial flutter. It is aesociatad with Iese intensive
reeource consumption without increasea in total energy delivery, anesthetic
requirements or complication.
[-[ Plasma Nitric~xideLeVe,sare Decreaeedin
Patients with Atrial Fibrillation
T. Minamino, M. Kitakaze, H. Sate, H. Asanuma, H. Funaya, K. Node,
Y. Koreteune, M. Hori. The First Dep. of Med., Osaka Univ. School of Med.,
Suita, Japan
Abnormalities of hemostatic condition are found in petienta with atrial fibril-
lation (Af), which may in part account for increased riekof thromboemboiiem.
Since nitric oxide (NO) exerta antithrombctic effeetaand the production of NO
is decreased under ‘WbulenF biood flow condition characteristic of Af, we
hypothesized that NO production ia deoreasad in patients with Af, which may
contribute to the abnormalities of hemostatic cxxsditione.Totest thia hypcthe-
sia,remeasured plaama NOlevels and hemostatic factors irt36pstients with
nonvalvuiar Af (age: 63+2, malalfemaie: 26/10) and 36 age, sex-matched
subjects with sinus rhythm (SR). There were not significant differenoas in the
prevalence of risk factors for stroke, the left atrial aize, and fractional short-
ening of left ventricle between the two groups. Plasma NO (nitrite+ nitrate)
